Infections, Antigen-Presenting Cells, T Cells, and Immune Tolerance: Their Role in the Pathogenesis of Immune Thrombocytopenia

Hematology/Oncology Clinics of North America

Volumn 23, Issue 6, 2009, Pages 1177-1192

  Semple, John W ^a,b,c,d  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c CANADIAN BLOOD SERVICES   (Canada)

^d Toronto Platelet Immunobiology Group   (Canada)

Author keywords

Autoimmunity; Immune tolerance; Platelets; T lymphocytes; Thrombocytopenia

Indexed keywords

DEXAMETHASONE; HLA ANTIGEN; IMMUNOGLOBULIN; RITUXIMAB; STEROID;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL DESTRUCTION; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DRUG MEGADOSE; GENETIC ANALYSIS; HELICOBACTER INFECTION; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INFECTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SPLENECTOMY; T LYMPHOCYTE; THROMBOCYTE;

ANIMALS; ANTIGEN-PRESENTING CELLS; HUMANS; IMMUNE TOLERANCE; INFECTION; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; T-LYMPHOCYTES;

EID: 70449650486     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2009.08.007     Document Type: Review

References (119)

1. Stasi R., Evangelista M.L., Stipa E., et al. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost 99 (2008) 4-13
2. Cines D.B., and Blanchette V.S. Immune thrombocytopenic purpura. N Engl J Med 346 (2002) 995-1008
3. Hou M., Stockelberg D., Kutti J., et al. Antibodies against GPIb/IX, GPIIb/IIIa, and other platelet antigens in chronic idiopathic thrombocytopenic purpura. Eur J Haematol 55 (1995) 307-314
4. Mehta Y.S., Pathare A.V., Badakere S.S., et al. Influence of auto-antibody specificities on the clinical course in patients with chronic and acute ITP. Platelets 11 (2000) 94-98
5. Fabris F., Scandellari R., Ruzzon E., et al. Platelet-associated autoantibodies as detected by a solid-phase modified antigen capture ELISA test (MACE) are a useful prognostic factor in idiopathic thrombocytopenic purpura. Blood 103 (2004) 4562-4564
6. Zhou B., Zhao H., Yang R.C., et al. Multi-dysfunctional pathophysiology in ITP. Crit Rev Oncol Hematol 54 (2005) 107-116
7. Cines D.B., Bussel J.B., Liebman H.A., et al. The ITP Syndrome: pathogenic and clinical diversity. Blood 113 (2009) 6511-6521
8. Michel M. Immune thrombocytopenic purpura: epidemiology and implications for patients. Eur J Haematol 82 Suppl 71 (2009) 3-7
9. Rodeghiero F., Stasi R., Gernsheimer T., et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113 (2009) 2386-2393
10. Semple J.W., and Freedman J. Abnormal cellular immune mechanisms associated with autoimmune thrombocytopenia. Transfus Med Rev 9 (1995) 327-338
11. Semple J.W. Immunobiology of T helper cells and antigen-presenting cells in autoimmune thrombocytopenic purpura (ITP). Acta Paediatr Suppl 424 (1998) 41-45
12. Coopamah M., Garvey M.B., Freedman J., et al. Cellular immune mechanisms in autoimmune thrombocytopenic purpura: an update. Transfus Med Rev 17 (2003) 69-80
13. Cooper N., and Bussel J. The pathogenesis of immune thrombocytopaenic purpura. Br J Haematol 133 (2006) 364-374
14. Wright J.F., Blanchette V., Wang H., et al. Characterization of platelet-reactive antibodies in children with varicella-associated acute immune thrombocytopenic purpura (ITP). Br J Haematol 95 (1996) 145-152
15. Chia W.K., Blanchette V., Mody M., et al. Characterization of HIV-1-specific antibodies and HIV-1-crossreactive antibodies to platelets in HIV-1-infected haemophiliac patients. Br J Haematol 103 (1998) 1014-1022
16. Takahashi T., Yujiri T., Shinohara K., et al. Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori-associated chronic idiopathic thrombocytopenic purpura. Br J Haematol 124 (2004) 91-96
17. Nardi M., Tomlinson S., Greco M., et al. Complement-independent, peroxide-induced antibody lysis of platelets in HIV-1-related immune thrombocytopenia. Cell 106 (2000) 551-561
18. Nardi M., Feinmark S.J., Hu L., et al. Complement-independent Ab-induced peroxide lysis of platelets requires 12-lipoxygenase and a platelet NADPH oxidase pathway. J Clin Invest 113 (2004) 973-980
19. Zhang W., Nardi M.A., Borkowsky W., et al. Role of molecular mimicry of HCV protein with platelet GPIIIa in hepatitis C-related immunologic thrombocytopenia. Blood 113 (2009) 4086-4093
20. Li Z., Nardi M.A., Wu J., et al. Platelet fragmentation requires a specific structural conformation of human monoclonal antibody against beta3 integrin. J Biol Chem 283 (2008) 3224-3230
21. Peterson J.A., Nyree C.E., Newman P.J., et al. A site involving the "hybrid" and PSI homology domains of GPIIIa (beta 3-integrin subunit) is a common target for antibodies associated with quinine-induced immune thrombocytopenia. Blood 101 (2003) 937-942
22. Peterson J.A., Nelson T.N., Kanack A.J., et al. Fine specificity of drug-dependent antibodies reactive with a restricted domain of platelet GPIIIA. Blood 111 (2008) 1234-1239
23. Aster R.H. Molecular mimicry and immune thrombocytopenia. Blood 113 (2009) 3887-3888
24. Musaji A., Cormont F., Thirion G., et al. Exacerbation of autoantibody-mediated thrombocytopenic purpura by infection with mouse viruses. Blood 104 (2004) 2102-2106
25. Gasbarrini A., Fracechi F., Tartaglione R., et al. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet 352 (1998) 878-879
26. Jarque I., Andreu R., Llopis I., et al. Absence of platelet response after eradication of Helicobacter pylori infection in patients with chronic idiopathic thrombocytopenic purpura. Br J Haematol 115 (2001) 1002-1003
27. Stasi R., Rossi Z., Stipa E., et al. Helicobacter pylori eradication in the management of patients with idiopathic thrombocytopenic purpura. Am J Med 118 (2005) 420-421
28. Janeway Jr. C.A. The immune system evolved to discriminate infectious nonself from noninfectious self. Immunol Today 13 (1992) 11-16
29. Medzhitov R., Preston-Hurlburt P., and Janeway Jr. C.A. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388 (1997) 394-397
30. Takeda K., Kaisho T., and Akira S. Toll-like receptors. Annu Rev Immunol 21 (2003) 335-376
31. Semple J.W., Aslam R., Speck E.R., et al. Murine platelets express Toll like receptor 2: a potential regulator of innate and adaptive immunity. Platelets 15 (2004) 267-268
32. Shiraki R., Inouea N., Kawasaki S., et al. Expression of Toll-like receptors on human platelets. Thromb Res 113 (2004) 379-385
33. Cognasse F., Hamzeh H., Chavarin P., et al. Evidence of Toll-like receptor molecules on human platelets. Immunol Cell Biol 88 (2005) 196-198
34. Andonegui G., Kerfoot S.M., McNagny K., et al. Platelets express functional Toll-like receptor-4 (TLR4). Blood 106 (2005) 2417-2423
35. Aslam R., Speck E.R., Kim M., et al. Platelet Toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-production in vivo. Blood 107 (2006) 637-641
36. Ståhl A.-L., Svensson M., Mörgelin M., et al. Lipopolysaccharide from enterohemorrhagic Escherichia coli binds to platelets via TLR4 and CD62 and is detected on circulating platelets in patients with hemolytic uremic syndrome. Blood 108 (2006) 167-176
37. Ward J.R., Bingle L., Judge H.M., et al. Agonists of toll-like receptor (TLR) 2 and TLR 4 are unable to modulate platelet activation by adenosine diphosphate and platelet activating factor. Thromb Haemost 94 (2005) 831-838
38. Patrignani P., Di Febbo C., Tacconelli S., et al. Reduced thromboxane biosynthesis in carriers of Toll-like 4 polymorphisms in vivo. Blood 107 (2006) 3572-3574
39. Clark S.R., Ma A.C., Tavener S.A., et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med 13 (2007) 463-469
40. Kuckleburg C.J., Tiwari R., and Czuprynski C.J. Endothelial cell apoptosis induced by bacteria-activated platelets requires caspase-8 and -9 and generation of reactive oxygen species. Thromb Haemost 99 (2008) 363-372
41. Semple J.W., Aslam R., Kim M., et al. Platelet-bound lipopolysaccharide enhances Fc receptor-mediated phagocytosis of IgG opsonized platelets. Blood 109 (2007) 4803-4805
42. Tremblay T., Aubin E., Lemieux R., et al. Picogram doses of lipopolysaccharide exacerbate antibody-mediated thrombocytopenia and reduce the therapeutic efficacy of intravenous immunoglobulin in mice. Br J Haematol 139 (2007) 297-302
43. Asahi A., Nishimoto T., Okazaki Y., et al. Helicobacter pylori eradication shifts monocyte Fcγ receptor balance toward inhibitory FcγRIIB in immune thrombocytopenic purpura patients. J Clin Invest 118 (2008) 2939-2949
44. Sinha A.A., Lopez T., and McDevitt H.O. Autoimmune diseases: the failure of self-tolerance. Science 248 (1990) 1380-1388
45. Schreuder G.M., Tilanus M.G., Bontrop R.E., et al. HLA-DQ polymorphism associated with resistance to type I diabetes detected with monoclonal antibodies, isoelectric point differences, and restriction fragment length polymorphism. J Exp Med 64 (1986) 938-943
46. Karpatkin S. Association of HLA-DRw2 with autoimmune thrombocytopenic purpura. J Clin Invest 63 (1979) 1085-1088
47. El-Khateeb M.S., Awidi A.S., Tarawneh M.S., et al. HLA antigens, blood groups and immunoglobulin levels in idiopathic thrombocytopenic purpura. Acta Haematol 76 (1986) 110-114
48. Goebel K.M., Hahn E., and Havermann K. HLA matching in autoimmune thrombocytopenic purpura. Br J Haematol 35 (1977) 341-342
49. Porges A., Bussel J., Kimberly R., et al. Elevation of platelet associated antibody levels in patients with chronic idiopathic thrombocytopenic purpura expressing the B8 and/or DR3 allotypes. Tissue Antigens 26 (1985) 132-137
50. Gratama J.W., D'Amaro J., deKoning J., et al. The HLA system in immune thrombocytopenic purpura: its relation to the outcome of therapy. Br J Haematol 56 (1984) 287-293
51. Gaiger A., Neumeister A., Heinzl H., et al. HLA class I and II antigens in chronic idiopathic autoimmune thrombocytopenia. Ann Hematol 68 (1994) 299-302
52. Nomura S., Matsuzaki T., Ozaki Y., et al. Clinical significance of HLA-DRB1*0410 in Japanese patients with idiopathic thrombocytopenic purpura. Blood 91 (1998) 3616-3622
53. Kuwana M., Kaburaki J., Pandey J.P., et al. HLA class II alleles in Japanese patients with immune thrombocytopenic purpura. Associations with anti-platelets glycoprotein antibodies and responses to splenectomy. Tissue Antigens 56 (2000) 337-343
54. Cao K., Hollenbach J., Shi X., et al. Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations. Hum Immunol 62 (2001) 1009-1030
55. Foster C.B., Zhu S., Erichsen H.C., et al. Polymorphisms in inflammatory cytokines and Fcgamma receptors in childhood chronic immune thrombocytopenic purpura: a pilot study. Br J Haematol 113 (2001) 596-599
56. Carcao M.D., Blanchette V.S., Wakefield C.D., et al. Fcgamma receptor IIa and IIIa polymorphisms in childhood immune thrombocytopenic purpura. Br J Haematol 120 (2003) 135-141
57. Sood R., Wong W., Jeng M., et al. Gene expression profile of idiopathic thrombocytopenic purpura (ITP). Pediatr Blood Cancer 47 (2006) 675-677
58. Panzer S. New therapeutic options for adult chronic immune thrombocytopenic purpura: a brief review. Vox Sang 94 (2008) 1-5
59. Psaila B., and Bussel J.B. Refractory immune thrombocytopenic purpura: current strategies for investigation and management. Br J Haematol 143 (2008) 16-26
60. Unanue E.R. Antigen-presenting function of the macrophage. Annu Rev Immunol 1 Suppl 2 (1984) 395-429
61. Lanzavecchia A. Receptor-mediated antigen uptake and its effect on antigen presentation to class II-restricted T lymphocytes. Annu Rev Immunol 8 (1990) 773-793
62. Watts C. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu Rev Immunol 15 (1997) 821-850
63. Cresswell P. Invariant chain structure and MHC class II function. Cell 84 (1996) 505-507
64. Bretscher P., and Cohn M. A theory of self-nonself discrimination. Science 169 (1970) 1042-1049
65. Linsley P.S., Clark E.A., and Ledbetter J.A. T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc Natl Acad Sci U S A 87 (1990) 5031-5036
66. Liu Y., and Linsley P.S. Costimulation of T cell growth. Curr Opin Immunol 4 (1992) 265-270
67. Lenschow D.J., Walunas T.L., and Bluestone J.A. CD28/B7 system of T cell costimulation. Annu Rev Immunol 14 (1996) 233-258
68. Fischer Lindahl K., and Wilson D.B. Histocompatibility antigen-activated cytotoxic T lymphocytes II. Estimates of frequency and specificity of precursors. J Exp Med 145 (1977) 508-522
69. The H.S., Harley E., Phillips R.A., et al. Quantitative studies on the precursors of cytotoxic lymphocytes I. Characteristics of a clonal assay and determination of the size of clones derived from single precursors. J Immunol 118 (1977) 1049-1056
70. Parker D.C. T cell-dependent B cell activation. Annu Rev Immunol 11 (1993) 331-360
71. Catani L., Fagioli M.E., Tazzari P.L., et al. Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. Exp Hematol 34 (2006) 879-887
72. Kissel K., Berbe S.R., Nockher A., et al. Human platelets target dendritic cell differentiation and production of proinflammatory cytokines. Transfusion 46 5 (2006) 818-827
73. Solanilla A., Pasquet J.M., Viallard J.F., et al. Platelet-associated CD154 in immune thrombocytopenic purpura. Blood 105 1 (2005) 215-218
74. Elzey B.D., Sprague D.L., and Ratliff T.L. The emerging role of platelets in adaptive immunity. Cell Immunol 238 (2005) 1-9
75. Hamzeh-Cognasse H., Cognasse F., Palle S., et al. Direct contact of platelets and their released products exert different effects on human dendritic cell maturation. BMC Immunol 9 (2008) 54-62
76. Hagihara M., Higuchi A., Tamura N., et al. Platelets, after exposure to a high shear stress, induce IL-10-producing, mature dendritic cells in vitro. J Immunol 172 (2004) 5297-5303
77. Czapigaa M., Kirk A.D., and Lekstrom-Himes J. Platelets deliver costimulatory signals to antigen-presenting cells: a potential bridge between injury and immune activation. Exp Hematol 32 (2004) 135-139
78. Li N. Platlet-lymphocyte cross-talk. J Leukoc Biol 83 (2008) 1069-1078
79. Semple J.W., and Freedman J. Increased antiplatelet T helper lymphocyte reactivity in patients with autoimmune thrombocytopenia. Blood 78 (1991) 2619-2625
80. Ware R.R., and Howard T.A. Phenotypic and clonal analysis of T lymphocytes in childhood immune thrombocytopenic purpura. Blood 82 (1993) 2137-2142
81. Filion M.C., Bradley A.J., Devine D.V., et al. Autoreactive T cells in healthy individuals show tolerance in vitro with characteristics similar to but distinct from clonal anergy. Eur J Immunol 25 (1995) 3123-3127
82. Shimomura T., Fujimura K., Takafuta T., et al. Oligoclonal accumulation of T cells in peripheral blood from patients with idiopathic thrombocytopenic purpura. Br J Haematol 95 (1996) 732-737
83. Semple J.W., Milev Y., Cosgrave D., et al. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood 87 (1996) 4245-4254
84. Guo C., Chu X., Shi Y., et al. Correction of Th1-dominant cytokine profiles by high-dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura. J Clin Immunol 27 (2007) 557-562
85. Wang T., Zhao H., Ren H., et al. Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura. Haematologica 90 (2005) 914-923
86. Liu F., Wu C., Yang X., et al. Polarization and apoptosis of T cell subsets in idiopathic thrombocytopenic purpura. Cell Mol Immunol 25 (2005) 387-392
87. Ogawara H., Handa H., Morita K., et al. High Th1/Th2 ratio in patients with chronic idiopathic thrombocytopenic purpura. Eur J Haematol 71 (2003) 283-288
88. Mouzaki A., Theodoropoulou M., Gianakopoulos I., et al. Expression patterns of Th1 and Th2 cytokine genes in childhood idiopathic thrombocytopenic purpura (ITP) at presentation and their modulation by intravenous immunoglobulin G (IVIg) treatment: their role in prognosis. Blood 100 (2002) 1774-1779
89. Kuwana M., Kaburaki J., and Ikeda Y. Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura. Role in production of anti-platelet autoantibody. J Clin Invest 102 (1998) 1393-1402
90. Kuwana M., Kaburaki J., Kitasato H., et al. Immunodominant epitopes on glycoprotein IIb-IIIa recognized by autoreactive T cells in patients with immune thrombocytopenic purpura. Blood 98 (2001) 130-139
91. Sukati H., Watson H.G., Urbaniak S.J., et al. Mapping helper T-cell epitopes on platelet membrane glycoprotein IIIa in chronic autoimmune thrombocytopenic purpura. Blood 109 (2007) 4528-4538
92. Olsson B., Andersson P.O., Jacobsson J.M., et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 9 (2003) 1123-1124
93. Zhang F., Chu K., Wang L., et al. Cell-mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpura. Eur J Haematol 76 (2006) 427-431
94. Sabnani I., and Tsang P. Therapeutic implications of T-cell clonopathy of unknown significance in chronic immune thrombocytopenic purpura. Platelets 20 (2009) 135-139
95. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6 (2005) 345-352
96. Tang Q., and Bluestone J.A. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol 9 (2008) 239-244
97. Hori S., Nomura T., and Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299 (2003) 1057-1061
98. Fontenot J.D., Gavin M.A., and Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory Tcells. Nat Immunol 4 (2003) 330-336
99. Korn T., Bettelli E., Oukka M., et al. IL-17 and Th17 cells. Annu Rev Immunol 27 (2009) 485-517
100. Bluestone J.A., and Abbas A.K. Natural versus adaptive regulatory T cells. Nat Rev Immunol 3 (2003) 253-257
101. Roncarolo M.G., Gregori S., Battaglia M., et al. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 212 (2006) 28-50
102. Jonuleit H., and Schmitt E. The regulatory T cell family: distinct subsets and their interrelations. J Immunol 171 (2003) 6323-6327
103. Korn T., and Oukka M. Dynamics of antigen-specific regulatory T-cells in the context of autoimmunity. Semin Immunol 19 (2007) 272-278
104. Valencia X., and Lipsky P.E. CD4+CD25+FoxP3+ regulatory T cells in autoimmune diseases. Nat Clin Pract Rheumatol 3 (2007) 619-626
105. Crispin J.C., Martinez A., and Alcocer-Varela J. Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun 21 (2003) 273-276
106. de Kleer I.M., Wedderburn L.R., Taams L.S., et al. CD4+CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. J Immunol 172 (2004) 6435-6443
107. Kukreja A., Cost G., Marker J., et al. Multiple immunoregulatory defects in type-1 diabetes. J Clin Invest 109 (2002) 131-140
108. Viglietta V., Baecher-Allan C., Weiner H.L., et al. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 199 (2004) 971-979
109. Sakakura M., Wada H., Tawara I., et al. Reduced Cd4+Cd25+ T cells in patients with idiopathic thrombocytopenic purpura. Thromb Res 120 (2007) 187-193
110. Ling Y., Cao X., Yu Z., et al. Circulating dendritic cells subsets and CD4+Foxp3+ regulatory T cells in adult patients with chronic ITP before and after treatment with high-dose dexamethasome. Eur J Haematol 79 (2007) 310-316
111. Liu B., Zhao H., Poon M.C., et al. Abnormality of CD4(+)CD25(+) regulatory T cells in idiopathic thrombocytopenic purpura. Eur J Haematol 78 (2007) 139-143
112. Arnold D.M., Dentali F., Crowther M.A., et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 146 (2007) 25-33
113. Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Brit J Haematol 141 (2008) 149-169
114. Stasi R., Del Poeta G., Stipa E., et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 110 (2007) 2924-2930
115. Stasi R., Cooper N., Del Poeta G., et al. Analysis of regulatory T cell changes in patients with idiopathic thrombocytopenic purpura receiving B-cell depleting therapy with rituximab. Blood 112 (2008) 1147-1150
116. Olsson B., Ridell B., Carlsson L., et al. Recruitment of T cells into bone marrow of ITP patients possibly due to elevated expression of VLA-4 and CX3CR1. Blood 12 (2008) 1078-1084
117. Yu J., Heck S., Patel V., et al. Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood 112 (2008) 1325-1328
118. McMillan R., Wang L., Tomer A., et al. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 103 (2004) 1364-1369
119. Zhang X.-L., Peng J., Sun J.-Z., et al. De novo induction of platelet-specific CD4(+)CD25(+) regulatory T cells from CD4(+)CD25(-) cells in patients with idiopathic thrombocytopenic purpura. Blood 113 (2009) 2568-2577